Invitrogen Corporation

(NASDAQ:IVGN)
  Sep 30, 2008 Jun 30, 2008 Mar 31, 2008 Dec 31, 2007
Operating revenue
Total Revenue 361,696 367,791 350,218 336,445
Operating Revenue 361,696 367,791 350,218 336,445
Adjustments To Revenue — — — —
Cost Of Sales 115,762 114,820 104,720 115,372
Cost Of Sales With Depreciation 143,542 125,268 131,458 142,224
Gross Operating Profit 245,934 252,971 245,498 221,073
Operating Expenses
Research And Development Expenses 31,430 33,173 30,633 31,213
Selling General And Administrative Expenses 118,301 115,526 113,733 106,842
Advertising Expenses — — — —
Operating Income Before Depreciation 96,203 104,272 101,132 83,018
Operating Income 35,346 74,995 73,893 55,320
Depreciation 27,780 27,864 26,738 26,852
Depreciation Unreconciled — — — —
Amortization — — — —
Amortization Of Intangibles — 17,416 — —
Operating Income After Depreciation 68,423 76,408 74,394 56,166
Non Operating Expenses
Interest Expense 6,860 6,895 6,867 6,906
Pre Tax Income 34,120 73,091 77,744 55,482
Income Taxes 8,892 19,866 19,374 14,982
Minority Interest — — — —
Income Before Income Taxes 34,120 73,091 77,744 55,482
Net Income From Continuing Operations 25,228 53,225 58,370 40,500
Net Income From Discontinued Operations — — 1,358 550
Net Income From Total Operations 25,228 53,225 59,728 41,050
Non Recurring Events
Extraordinary Income Losses — — — —
Income From Cummulated Effect Of Accounting Changes — — — —
Income From Tax Loss Carryforward — — — —
Other Gains And Losses — — — —
Total Net Income 25,228 53,225 59,728 41,050
Normalized Income 58,305 54,638 58,871 41,346
NetIncome Available For Common 25,228 53,225 58,370 40,500
Preferred Dividends — — — —
Excise Taxes — — — —